Evogene Ltd. - Ordinary Shares (EVGN)
2.2600
+1.1300 (100.00%)
NASDAQ · Last Trade: Jun 11th, 12:13 AM EDT
The company said its internal tests show a nearly 90% success in generating precise, novel molecules, vastly outperforming traditional generative AI models.
Via Stocktwits · June 10, 2025
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Via Chartmill · June 10, 2025
Via Benzinga · June 10, 2025
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Via Chartmill · June 10, 2025
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps.
Via Chartmill · June 10, 2025
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.
Via Chartmill · June 10, 2025
On Tuesday, there are stocks with unusual volume. Let's take a look.
Via Chartmill · April 22, 2025
Evogene's stock surged on news of ICL's acquisition of Lavie Bio's operations, strengthening ICL's position in ag-biologicals.
Via Benzinga · April 21, 2025

EVGN stock results show that Evogene missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 22, 2024

EVGN stock results show that Evogene beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 23, 2024

EVGN stock results show that Evogene beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
Via InvestorPlace · March 7, 2024

Evogene Ltd. released its fourth-quarter and full-year 2023 financial results, showing a 237% revenue increase for the year. Despite a 12% revenue decrease in Q4, the Israeli cannabis company reported $5.6 million in total revenue for the year. CEO Ofer Haviv highlighted the company's successful collaborations with industry leaders like Corteva, ICL, and Syngenta, contributing to revenue growth. In Q4, gross profit decreased to $180,000, but net financing income rose to $287,000. Total operating expenses increased to $7.8 million, leading to a net loss of $7.3 million. For the full year, gross profit reached $3.9 million, and net financing income was approximately $521,000. Evogene also secured partnerships with Verb Biotics and Colors Farm, along with receiving a €1.2 million EU grant for its Ag-Seed Division's research and development efforts.
Via Benzinga · March 7, 2024

Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million.
Via Benzinga · March 7, 2024

Evogene reports a strong Q3 with $3.8M revenue and significant gross profit growth, showcasing resilience and innovation in cannabis tech.
Via Benzinga · November 16, 2023

Via Benzinga · October 2, 2023

Evogene Ltd (NASDAQ: EVGN) shares are trading lower by 5.9% to $0.63 Thursday morning after the company received a letter from the Nasdaq indicating that the company is not in compliance with the minimum bid price rule.
Via Benzinga · September 21, 2023